NCT00831766 - Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 25, 2009

Primary Completion Date

February 17, 2015

Study Completion Date

November 16, 2020

Conditions

Myelodysplastic SyndromeAcute Myeloid Leukemia

Interventions

DRUG

Idarubicin

Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.

DRUG

Cytarabine

Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.

DRUG

Lenalidomide (Revlimid®)

Lenalidomide as outlined in Phase I and Phase II Treatment Arms.

Trial Locations (2)

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Cleveland Clinic - Taussig Cancer Institute, Cleveland